Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[212Pb] VMT-α-NET in Refractory/Relapsed Neuroendocrine Tumors
NCT06148636Phase 1Active, not recruiting
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of VMT-α-NET in neuroendocrine tumors (NETs) (5 arms). Primary endpoint: Recommended therapeutic dose of [212Pb] VMT-α-NET at 6 months. Started Nov 2023; status: active, not recruiting.
02
Drugs
VMT-α-NET
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT06148636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06148636.